Integral Diagnostics Ltd (ASX: IDX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Integral Diagnostics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $1.08 billion
P/E Ratio 20.28
Dividend Yield 1.93%
Shares Outstanding 233.96 million
Earnings per share -0.260
Dividend per share 0.06
Year To Date Return 60.52%
Earnings Yield 4.93%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Integral Diagnostics Ltd (ASX: IDX)
    Latest News

    Broker looking at the share price.
    Broker Notes

    Here's the latest broker upgrades on ASX All Ords shares

    Let's dive in.

    Read more »

    Doctor doing a telemedicine using laptop at a medical clinic
    Healthcare Shares

    3 small-cap ASX healthcare shares 'with strong prospects'

    Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

    Read more »

    Shot of a scientist using a computer while conducting research in a laboratory.
    Earnings Results

    Two up, one down: ASX healthcare stocks split after FY24 results

    The love wasn't shared evenly for these healthcare players today.

    Read more »

    young woman reviewing financial reports at desk with multiple computer screens
    Premium Reports

    ASX Reporting Season: The Importance Of The 'Equity' In Equities [PREMIUM CONTENT]

    One element of equities analysis that, I think, is rarely touched upon

    Read more »

    A man sees some good news on his phone and gives a little cheer.
    Share Gainers

    Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

    These shares are having a good session. But why?

    Read more »

    Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
    Broker Notes

    Buy 'em now! Brokers name 3 ASX All Ords shares to add to your portfolio

    Copper, technology, and healthcare are the themes among these newly buy-rated stocks.

    Read more »

    A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
    Share Fallers

    Why Bapcor, Chalice Mining, Integral Diagnostics, and Winsome Resources shares are dropping

    These shares are having a tough session on Monday. But why?

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Capitol Health, Capricorn Metals, Credit Clear, and Telix shares are storming higher

    These shares are starting the week with a bang. But why?

    Read more »

    Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
    Healthcare Shares

    This ASX All Ords stock is rocketing 20% after accepting a takeover offer

    These two diagnostics companies are planning to merge their operations.

    Read more »

    In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
    Healthcare Shares

    2 ASX healthcare shares to buy now for the AI revolution

    Experts expect mouth-watering growth from AI for these healthcare companies.

    Read more »

    Woman going for a scan reassured by doctor
    Healthcare Shares

    How AI could boost this ASX 300 healthcare stock

    The Firetrail investment management team see AI providing a 'material tailwind' for this stock.

    Read more »

    Shot of two young scientists using a laptop in a laboratory.
    Healthcare Shares

    2 ASX healthcare shares with 'compelling' valuations to buy

    The QVE team reckons this pair of small caps can be bought for cheap right now, but could rocket very…

    Read more »

    Frequently Asked Questions

    Yes, Integral Diagnostics historically pays two fully franked dividends a year.

    Integral Diagnostics generally pays its shareholder dividends in April and October.

    Integral Diagnostics Ltd listed on the ASX on 21 October 2015.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    30 Aug 2024 $0.0330 100.00% Final 03 Oct 2024
    29 Feb 2024 $0.0250 100.00% Interim 02 Apr 2024
    31 Aug 2023 $0.0350 100.00% Final 04 Oct 2023
    02 Mar 2023 $0.0250 100.00% Interim 04 Apr 2023
    01 Sep 2022 $0.0300 100.00% Final 05 Oct 2022
    01 Mar 2022 $0.0400 100.00% Interim 04 Apr 2022
    02 Sep 2021 $0.0700 100.00% Final 06 Oct 2021
    01 Mar 2021 $0.0550 100.00% Interim 06 Apr 2021
    28 Aug 2020 $0.0400 100.00% Final 01 Oct 2020
    28 Feb 2020 $0.0550 100.00% Interim 07 Apr 2020
    30 Aug 2019 $0.0500 100.00% Final 02 Oct 2019
    01 Mar 2019 $0.0500 100.00% Interim 02 Apr 2019
    31 Aug 2018 $0.0400 100.00% Final 04 Oct 2018
    31 Jan 2018 $0.0400 100.00% Interim 05 Mar 2018
    31 Aug 2017 $0.0000 100.00% Final 04 Oct 2017
    28 Feb 2017 $0.0300 100.00% Interim 30 Mar 2017
    31 Aug 2016 $0.0400 100.00% Final 04 Oct 2016

    IDX ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Integral Diagnostics Ltd

    Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services. 

    The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients. 

    The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.

    IDX Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $3.00 $0.10 3.45% 2,523,711 $2.92 $3.00 $2.90
    19 Dec 2024 $2.90 $-0.08 -2.68% 1,374,858 $2.92 $2.96 $2.90
    18 Dec 2024 $2.98 $0.04 1.36% 1,301,694 $2.91 $2.98 $2.84
    17 Dec 2024 $2.94 $-0.04 -1.34% 957,716 $2.96 $3.01 $2.92
    16 Dec 2024 $2.98 $-0.05 -1.65% 822,839 $3.03 $3.04 $2.97
    13 Dec 2024 $3.03 $0.03 1.00% 625,145 $3.04 $3.06 $2.99
    12 Dec 2024 $3.00 $-0.05 -1.64% 6,864,023 $3.05 $3.14 $3.00
    11 Dec 2024 $3.05 $0.12 4.10% 3,758,121 $3.05 $3.07 $2.96
    10 Dec 2024 $2.93 $0.03 1.03% 939,291 $2.89 $2.98 $2.89
    09 Dec 2024 $2.90 $0.02 0.69% 256,688 $2.93 $2.96 $2.90
    06 Dec 2024 $2.88 $-0.06 -2.04% 279,289 $2.95 $3.01 $2.88
    05 Dec 2024 $2.94 $-0.10 -3.29% 2,040,114 $3.06 $3.18 $2.94
    04 Dec 2024 $3.04 $0.10 3.40% 2,130,668 $2.94 $3.11 $2.88
    03 Dec 2024 $2.94 $0.09 3.16% 383,487 $2.87 $2.94 $2.85
    02 Dec 2024 $2.85 $-0.07 -2.40% 128,006 $2.89 $2.92 $2.82
    29 Nov 2024 $2.92 $0.01 0.34% 313,172 $2.91 $2.92 $2.86
    28 Nov 2024 $2.91 $0.08 2.83% 345,281 $2.82 $2.94 $2.78
    27 Nov 2024 $2.83 $-0.06 -2.08% 275,678 $2.88 $2.92 $2.79
    26 Nov 2024 $2.89 $-0.03 -1.03% 235,962 $2.92 $2.93 $2.87
    25 Nov 2024 $2.92 $0.02 0.69% 418,953 $2.93 $2.98 $2.90

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    07 Nov 2024 James Hall Buy 1,833 $5,425
    On-market trade.
    01 Nov 2024 Ian Kadish Issued 327,566 $979,422
    Issue of securities. 1,004,570 Rights
    16 Sep 2024 Ian Kadish Issued 29,072 $74,424
    Issue of securities. 677,004 Rights
    30 Aug 2024 Ian Kadish Exercise 26,035 $67,691
    Conversion of securities. 647,932 Rights,
    30 Aug 2024 Ian Kadish Issued 26,035 $67,691
    Conversion of securities.
    27 Aug 2024 Ian Kadish Expiry 184,616 $480,001
    As advised by the company. Lapsed, 673,967 Rights
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
    02 Apr 2024 James Hall Issued 1,719 $3,748
    Dividend Reinvestment Plan (DRP).

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Andrew James Fay Non-Executive Director Jul 2022
    Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. He is also Chair of the People and Culture Committee.
    Ms Raelene Margaret Murphy Non-Executive Director Oct 2017
    Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Ms Ingrid Anne Player Non-Executive Director Aug 2023
    Ms Player has more than 20 years of experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australia's largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specializing in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She is Chair of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Mr James Tobias Hall Non-Executive Director Sep 2023
    Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra and advisory board member for Fujitsu Australia and New Zealand. He is a Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
    Dr Ian Kadish Chief Executive OfficerManaging Director May 2017
    Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee. He is a Member of the Integral Clinical Leadership Committee.
    Mr John J Merity Interim Company Secretary Jun 2024
    -
    Ms Nikki Dalla Valle Company Secretary Dec 2023
    -
    Craig White Chief Financial Officer
    -
    Nikki Dalla Valle Company Secretary
    -
    John J Merity Interim Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Limited 42,793,666 18.29%
    J P Morgan Nominees Australia Pty Limited 39,158,798 16.74%
    HSBC Custody Nominees (Australia) Limited 38,626,662 16.51%
    HSBC Custody Nominees (Australia) Limited A/C 2 4,678,603 2.00%
    Warbont Nominees Pty Ltd (Unpaid Entrepot A/c) 4,119,561 1.76%
    Washington H Soul Pattinson And Company Limited 4,087,223 1.75%
    HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) 3,906,185 1.67%
    Citicorp Nominees Pty Limited (Colonial First State Inv A/C) 3,552,881 1.52%
    BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) 3,407,901 1.46%
    New Imaging Pty Ltd (New Imaging A/c) 3,389,045 1.45%
    Lethean Holdings Pty Ltd (Howitt No 8 A/c) 2,944,760 1.26%
    Firbar Pty Ltd (The Howitt No 4 A/c) 2,357,230 1.01%
    J A Mullins Pty Ltd (James A Mullins Family A/c) 2,316,051 0.99%
    Masfen Securities Limited 2,250,000 0.96%
    Mittal Holdings Pty Ltd (Howitt No 12 A/c) 2,085,907 0.89%
    Mr Vincent Michael O'Sullivan (O'Sullivan A/c) 2,020,000 0.86%
    Wyndham Salter Pty Ltd (The Howitt No 10 A/c) 1,792,947 0.77%
    A & S French Pty Ltd (The AJ French Family A/c) 1,778,327 0.76%
    BNP Paribas Nominees Pty Ltd (Agency Lending A/C) 1,711,682 0.72%
    BNP Paribas Noms Pty Ltd 1,636,566 0.70%

    Profile

    since

    Note